Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Biomedicines|January 21, 2023
The Relationship between the Oral Microbiota and Metabolic SyndromeYvonne Prince, Glenda M Davison, Saarah F G Davids, et al.
Journal of Diabetes Investigation|August 1, 2024
Investigating the altered expression of miR-486-5p and miR-novel-chr1_40444 in dysglycemia in a South African populationCecil J Weale, Chanelle Schroeder, Don M Matshazi, et al.
Frontiers in Genetics|October 1, 2021
Circulating Levels of MicroRNAs Associated With Hypertension: A Cross-Sectional Study in Male and Female South African ParticipantsDon M Matshazi, Cecil J Weale, Rajiv T Erasmus, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 30, 2020
Circulating miR-30a-5p and miR-182-5p in Prediabetes and Screen-Detected Diabetes MellitusCecil Jack Weale, Don M Matshazi, Saarah F G Davids, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
MicroRNAs-1299, -126-3p and -30e-3p as Potential Diagnostic Biomarkers for PrediabetesCecil J Weale, Don M Matshazi, Saarah F G Davids, et al.
Molecular Biology Reports|March 24, 2021
Two novel microRNAs and their association with absolute blood pressure parameters in an urban South African communityDon M Matshazi, Cecil J Weale, Rajiv T Erasmus, et al.
The Medical Journal of Australia|June 20, 1994
Extraordinary prevalence of non-insulin-dependent diabetes mellitus and bimodal plasma glucose distribution in the Wanigela people of Papua New GuineaG K Dowse, R A Spark, B Mavo, et al.
Frontiers in Genetics|September 27, 2021
Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on TreatmentCecil J Weale, Don M Matshazi, Saarah F G Davids, et al.
Frontiers in Cardiovascular Medicine|May 3, 2021
MicroRNA Profiles in Normotensive and Hypertensive South African IndividualsDon M Matshazi, Cecil J Weale, Rajiv T Erasmus, et al.
Metabolic Brain Disease|April 28, 2021
Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part I. Targeting a metabolic model rather than autoimmunitySusan J van Rensburg, Ronald van Toorn, Rajiv T Erasmus, et al.
Pageof 19